Primary Angiosarcoma of the Adrenal Gland: Report of 2 Cases and Review of the Literature

2021 ◽  
pp. 106689692110200
Author(s):  
Alexander Ladenheim ◽  
Miao Tian ◽  
Alaa Afify ◽  
Michael Campbell ◽  
Elham Kamangar
Keyword(s):  
Local Recurrence ◽  
Adrenal Gland ◽  
Median Survival ◽  
Middle Age ◽  
Review Of The Literature ◽  
Vascular Neoplasm ◽  
Primary Angiosarcoma ◽  
Adrenocortical Adenomas

Primary adrenal angiosarcoma is a rare, malignant, vascular neoplasm. These neoplasms typically arise in middle age (median age of 60 years) and are more common in males (65%) than in females. Although rare, these neoplasms are aggressive with a propensity for local recurrence and metastasis and a median survival of 18 months. We present 2 cases of primary adrenal angiosarcoma with synchronous, ipsilateral adrenocortical adenomas. We review the cases of adrenal angiosarcoma reported since 1988 and discuss their clinical and histopathologic characteristics.

scholarly journals Review of the Literature on Leiomyoma and Leiomyosarcoma of the Adrenal Gland: A Systematic Analysis of Case Reports

In Vivo ◽  
2020 ◽  
Vol 34 (5) ◽  
pp. 2233-2248
Author(s):  
MARIA SAKELLARIOU ◽  
DIONYSIOS DELLAPORTAS ◽  
MELPOMENI PEPPA ◽  
DIMITRIOS SCHIZAS ◽  
EMMANOUIL PIKOULIS ◽  
...  
Keyword(s):  
Adrenal Gland ◽  
Case Reports ◽  
Review Of The Literature ◽  
Systematic Analysis

scholarly journals Surgery results in low relapse and progression rates in extramedullary plasmacytoma of the head and neck: A case cohort and review of the literature

2020 ◽  
Vol 12 (2) ◽  
Author(s):  
Matevz Skerget ◽  
Tadej Dovsak ◽  
Gregor Kos ◽  
Samo Zver
Keyword(s):  
Multiple Myeloma ◽  
Local Recurrence ◽  
Head And Neck ◽  
Treatment Option ◽  
Local Control ◽  
Extramedullary Plasmacytoma ◽  
Initial Evaluation ◽  
Review Of The Literature

Extramedullary plasmacytoma of the head and neck is a rare indolent neoplasm. Radiotherapy is often the preferred treatment option with excellent local control and survival. The risk of local recurrence or transformation to multiple myeloma is 10- 30%. In our case-cohort, thorough, sensitive initial evaluation for disseminated clonal disease and the incorporation of surgery led to excellent results with no recurrences or systemic progression.

scholarly journals Angiosarcoma of the Heart: Case Report

2020 ◽  
Vol 3 (11) ◽  
pp. 01-07
Author(s):  
Marc Vanderheyden ◽  
Sofie Dhaeyer ◽  
Chirik Wah Lau ◽  
Vanessa Meert ◽  
Jan Leeman ◽  
...  
Keyword(s):  
Case Report ◽  
Malignant Tumors ◽  
Local Relapse ◽  
Review Of The Literature ◽  
Poor Survival ◽  
Right Heart ◽  
Course Of Disease ◽  
Metastatic Recurrence ◽  
Primary Angiosarcoma ◽  
The Right

Cardiac angiosarcomas are rare malignant tumors, predominantly affecting the right heart with poor survival outcomes. The current mainstay of treatment consists of surgery with or without chemotherapy, but often yields limited results with local relapse or metastatic recurrence. This case report describes 2 patients with primary angiosarcoma located in the right atrium. One patient received neo-adjuvant and adjuvant chemotherapy; both were scheduled for surgical resection. The course of disease is described followed by a comprehensive review of the literature.

scholarly journals Schwannoma of the Adrenal Gland: A Rare Adrenal Incidentaloma: Case Report and Review of the Literature

2015 ◽  
Vol 144 (suppl 2) ◽  
pp. A318-A318
Author(s):  
Muhammad Khurram ◽  
Ameer Hamza ◽  
Laurence Briski ◽  
Ahmad Ibrahim
Keyword(s):  
Case Report ◽  
Adrenal Gland ◽  
Adrenal Incidentaloma ◽  
Review Of The Literature

scholarly journals Adrenal gland injury after blunt abdominal trauma: Two case series and review of the literature

2020 ◽  
Vol 67 ◽  
pp. 34-38
Author(s):  
Konstantinos S. Papadopoulos ◽  
Konstantinos Strigklis ◽  
Kleoniki Kordeni ◽  
Panagiota Xaplanteri ◽  
Georgios Zacharis
Keyword(s):  
Adrenal Gland ◽  
Abdominal Trauma ◽  
Blunt Abdominal Trauma ◽  
Case Series ◽  
Review Of The Literature

scholarly journals A giant solitary fibrous tumor of the adrenal gland in a 13-year old: a case report and review of the literature

2019 ◽  
Vol 13 (1) ◽  
Author(s):  
Hailu Wondimu Gebresellassie ◽  
Yusuf Mohammed ◽  
Brahenu Kotiso ◽  
Bereket Amare ◽  
Aemero Kebede
Keyword(s):  
Case Report ◽  
Adrenal Gland ◽  
Solitary Fibrous Tumor ◽  
Review Of The Literature ◽  
Fibrous Tumor

scholarly journals Cervical Chordoma with Retropharyngeal Extension Presenting with Impaired Voice

2008 ◽  
Vol 94 (6) ◽  
pp. 873-876 ◽  
Author(s):  
Keyvan Nicoucar ◽  
Thierry Rausch ◽  
Minerva Becker ◽  
Pavel Dulguerov
Keyword(s):  
Local Recurrence ◽  
World Literature ◽  
Malignant Tumors ◽  
Proton Beam Therapy ◽  
Voice Disorder ◽  
Review Of The Literature ◽  
High Propensity ◽  
Tumors Of Bone ◽  
Aggressive Tumor ◽  
Cervical Chordoma

Aims and Background We report an extremely rare case of cervical chordoma presenting with impaired voice. Method Case report and a review of the literature concerning the presentation, diagnosis, and treatment of a cervical chordoma. Results A singing teacher complaining of dysphonia was examined and surgically treated for a retropharyngeal extension of a cervical chordoma. A local recurrence was treated with proton beam therapy. Among primary malignant tumors of bone, chordomas account for 3–4% of all cases. Chordoma is typically a locally aggressive tumor with a high propensity for local recurrence. Its management involves surgery, radiotherapy, or both. Conclusion To our knowledge this is the first report in the world literature of a retropharyngeal extension of a cervical chordoma presenting with impaired voice. This case indicates that bony tumors of the spine may present first to voice-disorder clinicians. Increased awareness of this neoplasm may lead to earlier diagnosis and better treatment.

Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.

1989 ◽  
Vol 7 (9) ◽  
pp. 1239-1251 ◽  
Author(s):  
P P Rosen ◽  
S Groshen ◽  
P E Saigo ◽  
D W Kinne ◽  
S Hellman
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Local Recurrence ◽  
Median Survival ◽  
Tumor Size ◽  
Stage I ◽  
Axillary Lymph ◽  
Axillary Lymph Node Metastases ◽  
Systemic Recurrence

Prognostic factors have been examined in 644 patients with tumor-node-metastasis (TNM) stage T1 breast carcinoma treated by mastectomy and followed for a median of 18.2 years. Overall, 148 patients (23%) died of recurrent breast carcinoma. Eighteen (3%) were alive with recurrent disease and 478 (74%) were alive or died of other causes without recurrence. Unfavorable clinicopathologic features were larger tumor size (1.1 to 2.0 cm v less than or equal to 1 cm), perimenopausal menstrual status, the number of axillary lymph node metastases, poorly differentiated grade, presence of lymphatic tumor emboli (LI) in breast tissue near the primary tumor, blood vessel invasion (BVI), and an intense lymphoplasmacytic reaction around the tumor. Median survival after recurrence for the entire series was 2 years. This was not significantly influenced by tumor size, the number of axillary nodal metastases, the type of treatment for recurrence, or the interval to recurrence. The proportions surviving 5 and 10 years after recurrence were 17% and 5%, respectively. Among T1N0M0 cases, the chance of a local recurrence was 2.8% within 20 years. Median survival of T1N0M0 cases after local recurrence (4.5 years) was significantly longer than after systemic recurrence (1.5 years). A similar trend (3.7 v 2.0 years), not statistically significant, was seen in T1N1M0 patients, who had a 6.5% chance of local recurrence within 20 years. Median survival following systemic recurrence detected 10 or more years after diagnosis in T1N0M0 and in T1N1M0 patients was significantly longer than the median survival for systemic recurrences found in the first decade of follow-up. This difference did not apply following local recurrence in either T1N0M0 or T1N1M0 cases. It is evident that patients with T1 breast carcinoma can be subdivided into differing prognostic groups and this must be taken into account when considering the role of adjuvant chemotherapy for stage I disease. Systemic adjuvant treatment may prove to be beneficial for patients with unfavorable prognostic factors, while women with an especially low risk for recurrence (eg, T1N0M0 tumor 1.0 cm or less) might be spared such treatment.

Sign in / Sign up

Export Citation Format

Share Document